Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., . . . Ignatius Ou, S. (2015). Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer. Lancet Oncol.
استشهاد بنمط شيكاغوShaw, Alice T., et al. "Phase 2 Prospective Analysis of Alectinib in ALK-positive, Crizotinib-resistant Non-small-cell Lung Cancer." Lancet Oncol 2015.
MLA استشهادShaw, Alice T., et al. "Phase 2 Prospective Analysis of Alectinib in ALK-positive, Crizotinib-resistant Non-small-cell Lung Cancer." Lancet Oncol 2015.
تحذير: قد لا تكون هذه الاستشهادات دائما دقيقة بنسبة 100%.